Fig. 6.

Reduced PCDH17 expression predicts a worse outcome in the molecularly defined subgroups of AML patients. a–d Kaplan–Meier curves of OS stratified by PCDH17 in the genetically defined subgroups of AML patients, as indicated. Low PCDH17 expression is associated with poor outcome in all subgroups. e, f Kaplan–Meier curves of OS in the TCGA (e) and the GSE12417 cohort 1 (f) as stratified by the LSC17 signature. The low- and high-risk patients were further dichotomized by PCDH17 expression status. PCDH17 expression status could further stratify survival in the subgroup with low LSC17 score. Patients were separated into high and low PCDH17 group based on the median expression levels of PCDH17